- KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024
- KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year
- KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
- KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
- KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
- KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
- KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas
- KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer
More ▼
Key statistics
As of last trade, Kalvista Pharmaceuticals Inc (4XC1:STU) traded at 10.40, 54.07% above the 52 week low of 6.75 set on Nov 24, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.70 |
---|---|
High | 10.70 |
Low | 10.10 |
Bid | 10.30 |
Offer | 10.60 |
Previous close | 10.70 |
Average volume | 0.00 |
---|---|
Shares outstanding | 42.19m |
Free float | 41.67m |
P/E (TTM) | -- |
Market cap | 476.31m USD |
EPS (TTM) | -3.14 USD |
Data delayed at least 15 minutes, as of May 23 2024.
More ▼